Enclomiphene vs Liothyronine (T3)
A side-by-side research comparison of Enclomiphene and Liothyronine (T3) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Enclomiphene | Liothyronine (T3) |
|---|---|---|
| Full name | Enclomiphene Citrate | Liothyronine Sodium (Cytomel) |
| Category | Hormone Replacement | Hormone Replacement |
| Status | Investigational drug | Prescription medication |
| Mechanism | Blocks estrogen receptors in the hypothalamus, reducing negative feedback and increasing GnRH pulsatility, which stimulates LH and FSH release for endogenous testosterone production. | Binds nuclear thyroid receptors to regulate gene transcription for basal metabolic rate, thermogenesis, protein synthesis, and carbohydrate/fat metabolism in virtually every tissue. |
| Molecular weight | 598.09 Da | 650.97 Da |
| Half-life | 10-14 hours | ~2.5 days |
| Bioavailability | ~50% oral | ~95% oral |
| Typical dose | 12.5-25 mg | 5-25 mcg |
| Frequency | Daily | Daily (split AM/PM) |
| Route | Oral capsule | Oral tablet or sustained-release capsule |
Enclomiphene reported benefits
- Increased endogenous testosterone
- Preserved fertility
- Improved libido
- Enhanced energy and mood
- No testicular atrophy
Liothyronine (T3) reported benefits
- Metabolic rate increase
- Weight loss support
- Improved energy
- Better mood
- Reduced brain fog
- Enhanced fat oxidation
Related comparisons
Research and educational reference only. Not medical advice.